US 12,280,027 B2
Transdermal analgesic formulation
Paul Mills, North Sydney (AU); and Nana Satake, North Sydney (AU)
Assigned to MEAT & LIVESTOCK AUSTRALIA LTD, North Sydney (AU)
Appl. No. 16/772,027
Filed by MEAT & LIVESTOCK AUSTRALIA LTD, North Sydney (AU)
PCT Filed Dec. 11, 2018, PCT No. PCT/AU2018/000255
§ 371(c)(1), (2) Date Jun. 11, 2020,
PCT Pub. No. WO2019/113625, PCT Pub. Date Jun. 20, 2019.
Claims priority of application No. 2017904975 (AU), filed on Dec. 11, 2017.
Prior Publication US 2021/0069137 A1, Mar. 11, 2021
Int. Cl. A61K 31/192 (2006.01); A61K 9/00 (2006.01); A61K 31/196 (2006.01); A61K 31/44 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/44 (2017.01); A61P 29/00 (2006.01)
CPC A61K 31/192 (2013.01) [A61K 9/0017 (2013.01); A61K 31/196 (2013.01); A61K 31/44 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/44 (2013.01); A61P 29/00 (2018.01)] 6 Claims
 
1. A method of treating inflammation in a subject, the method including the step of topically administering to an area of the subject a therapeutically effective amount of a transdermal liquid formulation comprising:
(a) a therapeutically effective amount of ketoprofen or a pharmaceutically acceptable salt thereof; and
(b) a dermal penetration enhancer comprising an alcohol, an emollient and eucalyptus oil;
to thereby provide a therapeutically effective plasma concentration of ketoprofen or a pharmaceutically acceptable salt thereof to the subject to thereby treat inflammation in the subject,
wherein:
the subject is bovine;
the inflammation is systemic, or is located at a site of the subject which is not at the area of administration of the transdermal liquid formulation;
the ketoprofen is present in the transdermal liquid formulation in an amount from 100 mg/mL to 300 mg/mL;
the alcohol is ethanol, and is present in the transdermal liquid formulation in an amount from 100 mg/mL to 700 mg/mL;
the emollient is selected from the group consisting of propylene glycol, oleyl alcohol, dimethyl isosorbide, PPG-3 benzyl ether myristate, di-PPG2-myreth-10-adipate, 1-ethyl-2-pryrrolidone, isomyristate, isopropyl myristate and any combination thereof, and is present in the transdermal liquid formulation in an amount from 100 mg/mL to 700 mL/L; and
the eucalyptus oil is present in an amount from 25 mL/L to 150 mL/L.